F S&P 500
5,107.25 +15.75 (+0.31%) F Dow Jones
38,619.00 +237.00 (+0.62%) F Nasdaq
17,766.25 +116.50 (+0.66%) E-mini Russell 2000 Index Futur
2,023.20 -4.00 (-0.20%) Petróleo
79.15 +0.20 (+0.25%) Oro
2,310.60 +1.00 (+0.04%)
Poniard Pharmaceuticals, Inc. (PARD)
Poniard Pharmaceuticals, Inc.
300 Elliott Avenue West
Suite 530
Seattle, WA 98119
United States
206 281 7001
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 7
Descripción
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Gestión corporativa
La calificación ISS Governance QuickScore de Poniard Pharmaceuticals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
